key: cord-0810536-1iagbaow authors: Irfan, Omar; Muttalib, Fiona; Tang, Kun; Jiang, Li; Lassi, Zohra S; Bhutta, Zulfiqar title: Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis date: 2021-02-16 journal: Arch Dis Child DOI: 10.1136/archdischild-2020-321385 sha: 179ff9be1c337504f015413ce5316b6983532470 doc_id: 810536 cord_uid: 1iagbaow OBJECTIVE: Compare paediatric COVID-19 disease characteristics, management and outcomes according to World Bank country income level and disease severity. DESIGN: Systematic review and meta-analysis. SETTING: Between 1 December 2019 and 8 January 2021, 3350 articles were identified. Two reviewers conducted study screening, data abstraction and quality assessment independently and in duplicate. Observational studies describing laboratory-confirmed paediatric (0–19 years old) COVID-19 were considered for inclusion. MAIN OUTCOMES AND MEASURES: The pooled proportions of clinical findings, treatment and outcomes were compared according to World Bank country income level and reported disease severity. RESULTS: 129 studies were included from 31 countries comprising 10 251 children of which 57.4% were hospitalised. Mean age was 7.0 years (SD 3.6), and 27.1% had a comorbidity. Fever (63.3%) and cough (33.7%) were common. Of 3670 cases, 44.1% had radiographic abnormalities. The majority of cases recovered (88.9%); however, 96 hospitalised children died. Compared with high-income countries, in low-income and middle-income countries, a lower proportion of cases were admitted to intensive care units (ICUs) (9.9% vs 26.0%) yet pooled proportion of deaths among hospitalised children was higher (relative risk 2.14, 95% CI 1.43 to 3.20). Children with severe disease received antimicrobials, inotropes and anti-inflammatory agents more frequently than those with non-severe disease. Subgroup analyses showed that a higher proportion of children with multisystem inflammatory syndrome (MIS-C) were admitted to ICU (47.1% vs 22.9%) and a higher proportion of hospitalised children with MIS-C died (4.8% vs 3.6%) compared with the overall sample. CONCLUSION: Paediatric COVID-19 has a favourable prognosis. Further severe disease characterisation in children is needed globally. The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 has spread from a local outbreak in China to a global pandemic within months. On 31 December 2019, a cluster of cases with pneumonia of unknown cause emerged from Wuhan, China. On 30 January 2020, the WHO declared the coronavirus outbreak a Public Health Emergency of International Concern, and on 11 March 2020, a pandemic. As of 21 January 2021, there have been over 95.6 million confirmed COVID-19 cases and over 2.0 million associated deaths from 216 countries, areas or territories. 1 Children under-19 years of age comprise a small proportion (1%-10%) of the total reported cases 2-5 with a lower risk of developing critical illness from COVID-19 infection compared with adults. 6 Prior systematic reviews of paediatric COVID-19 have described a mild disease in children with good outcomes. 4 7 8 Since the publication of these reviews, the pandemic has spread extensively around the globe. In addition to pulmonary manifestations of COVID-19 in children, reports from Europe, North America, Latin America and Asia have emerged, describing a multisystem inflammatory syndrome children (MIS-C) related to COVID-19 infection. [9] [10] [11] [12] COVID-19 has also disrupted essential maternal and child health interventions, including outpatient visits and vaccinations for young children in most countries, further worsening the existing burden on healthcare provision and delivery. 13 The objective of this review, in addition to providing a comprehensive update of the evolving paediatric COVID-19 literature, is a unique comparison of reported cases in low-income and middle-income countries (LMICs) to high-income countries (HICs) and of children with severe versus non-severe disease. Furthermore, the review provides a subgroup analysis of children presenting with symptoms of MIS-C and neonatal cases. The protocol of the review is registered with PROSPERO (CRD42020183134). This systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Metaanalysis (PRISMA). The review includes a comprehensive search of MEDLINE, Embase, WHO COVID-19 Database, Chinese COVID-19 Databases (CNKI and Wangfang), Latin-American and Caribbean Health Sciences Literature (LILACS) from 1 December 2019 to 8 January 2021. Complementary searches were conducted in Google Scholar, John Hopkins Health Resource, WHO news and the Chinese and US CDC Library. MedRxiv, BioRxiv and ChinaXiv Global child health were searched for preprints. No language restrictions were applied. A search strategy was formulated and administered as shown in online supplemental table 1. Observational studies reporting children (0-19 years old) with laboratory-confirmed COVID-19 (serology or RT-PCR) were considered for inclusion. Studies with a subset of children 0-19 years were included if disaggregated data for children were provided. Studies were screened for any overlap in paediatric cases by reviewing institution details and the period reported. Review articles, case reports, commentaries and letters not presenting any original data were excluded. Case reports were excluded to reduce risk of selection bias and over-representation of extreme cases. Covidence Software (2016) was used for screening by two reviewers independently and in duplicate. Key reference lists were screened for additional studies. Two reviewers conducted data extraction using a prepiloted data form. Data extracted included authors' names, date of publication, study-design, city, country, number of cases, gender, comorbidities, travel and contact history, diagnostic tests for COVID-19, clinical details, laboratory tests, radiological findings, management and outcomes. Disaggregated data by age groups (0-5 years, 5-10 years and >10 years old) and reported disease severity was extracted where available. Criteria for severe disease were as defined within each individual study and included admission to intensive care units (ICUs), use of mechanical ventilation, multiorgan failure and presence of hypoxia (oxygen saturation <92%). Individual study quality was evaluated independently by the review authors using quality assessment tools developed by the National Heart Lung and Brain Institute (NHLBI) 14 (https:// www. nhlbi. nih. gov/ health-topics/ study-quality-assessmenttools). Study quality was scored out of 8, based on clarity of study objectives, case definition, consecutive inclusion of cases, comparability of included patients, definition and measurement of outcomes, length of follow-up, statistical methods and results. Studies with score 6-8 were considered to be good quality, 4-5 considered fair quality and <4 considered poor quality. Categorical data were summarised as counts and proportions. The pooled proportions of reported findings were calculated using Comprehensive Meta-Analysis 2.2.027 using randomeffects model. I 2 was calculated to examine statistical heterogeneity (I 2 >50% considered high heterogeneity). The clinical features and outcomes were compared according to (1) World Bank country income level (HICs versus LMICs) 15 and (2) reported disease severity (severe versus non-severe) using pooled proportions and their 95% CIs, supplemented by relative-risk (RR). Subgroup analyses of children with MIS-C and neonatal cases were conducted. After removal of duplicates, 3350 citations were screened for inclusion. Full texts of 198 studies were screened and 129 studies 2 3 9-12 16-138 were included (online supplemental figure 1 ). Sixty-nine studies were excluded as they either presented overlapping data, did not provide age-disaggregated data for children or were commentaries, editorials or reviews. In terms of study setting, 13 studies were population-based national surveillance studies, 94 studies included only children admitted to hospital and 22 studies reported patients presenting to outpatient clinics or emergency departments (hospitalisation rate of 24.2%, 385/1590). Sixty studies were from HICs (n=6528) and 69 studies from LMICs (n=3723). Almost onethird of included studies were from China (36/129, 28.0%), 2 A total of 9335 children from the 129 case series were included in the meta-analysis. Of 8455 children for whom initial disposition was reported, 4851 were hospitalised (57.4%). Among them, 55.5% were men. The patient's ages ranged from 0 to 17 years with mean age of 7.0±3.6 years. Ninety-one of the 129 studies reported age-disaggregated data for infection incidence as shown in online supplemental table 4. Nearly half of the cases were >10 years of age. Contact exposure to COVID-19 was reported in 64.0% of cases. Travel history to an epicentre was reported in 13.0% cases. At-least one underlying comorbidity was reported in 27.1% of cases. The most common reported comorbidities were immunosuppression (15.8%) and lung disease (12.5%). Table 1 summarises the clinical manifestations reported in the studies. There were 13.1% asymptomatic cases (95% CI 10.4% to 16.3%) who presented primarily through contact exposure in family-clusters (parents, siblings and other relatives). The most common presenting symptoms were fever (63.3%, 95% CI 58.6% to 68.4%) and cough (33.7%, 95% CI 29.6% to 38.1%) followed by nausea or vomiting (20.0%, 95% CI 16.5% to 24.0%) and diarrhoea (19.6%, 95% CI 16.1% to 23.7%). Other symptoms included dyspnoea, nasal-symptoms, rashes, kawasaki-like symptoms, conjunctivitis, fatigue, abdominal pain and neurological symptoms. Sixty-seven of the 129 studies reported age disaggregated data for clinical features (online supplemental table 5). Clinical features were similar in the three age groups: ≤5 years, >5 to ≤10 years, >10 years with higher prevalence of abdominal symptoms in children>5 years. One thousand five hundred and thirty cases out of 3670 (44.1%, 95% CI 39.5% to 48.9%) cases had radiological abnormalities; ground glass opacities (27.4%) were the most commonly reported abnormality. Sixty-six studies provided details on laboratory-markers ( One thousand three hundred and fifty-nine patients (22.9%, 95% CI 17.6% to 29.2%) were admitted to ICUs (table 3) . Thirty-eight studies provided disaggregated data for severe cases (table 4) . A higher proportion of children with severe disease had symptoms consistent with MIS-C and received antimicrobials, inotropes and anti-inflammatory agents compared with those with non-severe disease. There were no deaths among children Global child health Global child health Of the included studies that reported clinical characteristics and outcomes, 60 studies were from HICs (n=6528) and 69 studies from LMICs (n=3723) as show in Thirty-one studies (n=1208) with 22 from HIC (n=602), reported series of children presenting with MIS-C. Fever, abdominal pain and diarrhoea were the most common symptoms. Nearly half of children (638/1208) who met criteria for MIS-C were admitted to ICU (449/638, 70.3% of which were from HIC) compared with 22.9% in the overall analysis (online supplemental tables 6 and 7). Disaggregated data were available on 184 neonates with fever; inability to feed/lethargy and dyspnoea were the most commonly reported symptoms. Twenty-one neonates (16.6%, 95% CI 11.2% to 23.9%) were asymptomatic at the time of diagnosis. One hundred and twenty-one studies were determined to be of good quality while eight were of fair quality (online supplemental table 8). Studies were primarily downgraded for incomplete case definition, 29 129 134-136 which raises concern that the included sample could be biased towards more severe presentations. Global knowledge of COVID-19 epidemiology, clinical characteristics and management has continued to evolve since the onset of the pandemic. Children have been noted to have relatively lower rates of severe illness and low mortality; however, they have been impacted by MIS-C. 4 139 The findings of our review, the largest in terms of published systematic reviews on paediatric COVID-19, are consistent with previous reviews that identified predominance of infection in school-age children, slight male predisposition, prevalence of comorbidities among children with COVID-19 and low hospitalisation and mortality rates. 2 4 140 The clinical presentation in children is heterogeneous, including a wide spectrum of clinical features. Fever and cough were the most commonly reported presenting symptoms, in line with the previously published systematic reviews. 4 141 A U-shaped curve of severity has been demonstrated in children diagnosed with COVID-19 with infants under 1 year of age and adolescents 10-14 years of age at higher risk of developing severe COVID-19. 3 47 75 Due to lack of age-disaggregated data, we could not reliably compare the frequency of severe cases by age group in this review. Reported risk factors for severe disease among children include age, viral load 142 and presence of comorbidities. 3 There is a possibility that children with comorbidities may have been hospitalised related to their underlying chronic condition and incidentally determined to have COVID-19 infection or investigated more extensively. Some of the common comorbidities reported in children with COVID-19 infection include asthma, immunosuppression, congenital heart disease, kidney disease and obesity. 3 4 47 Regional differences were identified in the comparison of clinical features, treatment and outcomes between HICs and LMICs. Pooled estimates of hospital mortality were higher in LMICs compared with HICs. Given that it was not possible to calculate risk-adjusted mortality rates for COVID-19, it is unclear whether observed differences in mortality are related to selection bias (eg, differences in severity of illness of included patients or differences in case definitions and inclusion criteria) or differences in available hospital resources. Nevertheless, there is ongoing concern that, in LMICs with high burden of illness and health system limitations, children with severe disease and MIS-C may be at greater risk for adverse outcomes and death than perceived to date. The differences in frequency of observed clinical features may be related to increasing recognition of MIS-C over the course of the pandemic and their inclusion in more recent COVID-19 case series, but is likely similar between HICs and LMICs. Comparisons of clinical features and outcomes according to severity of illness were limited by heterogeneous reporting across the included case series. A higher proportion of children with severe disease demonstrated symptoms consistent with MIS-C (fever, abdominal symptoms, rash, neurological symptoms, conjunctivitis) and received IVIG, steroids and inotropes. Compared with previous reviews, several at an earlier stage of the pandemic, 4 7 8 140 143 this review has several strengths. Using a broad search strategy implemented in English, Chinese and Spanish databases, we summarise evidence from 129 studies from 31 different countries, the largest sample to-date. We excluded case reports to minimise selective reporting of extreme and atypical cases. We also attempted to reduce possible overlap in cases to prevent duplications. We identified differences in features from studies in HICs compared with LMICs, and between severe and non-severe cases, although with limited available data. Finally, we report subgroup analyses for neonates, and children presenting with MIS-C. The review is limited primarily by the small sample sizes of individual studies, limitations in study reporting, and study quality limitations due to non-consecutive patient enrolment, unclear case definition and incomplete follow-up to hospital discharge. Our approach of pooling proportions is subject to bias and wide confidence-intervals due to small study sample size. We could not undertake multivariate analysis to identify risk factors for severe infection or adverse outcome in children due to lack of individual-patient-data. The inclusion of asymptomatic cases could have contributed to underestimation of the prevalence of clinical characteristics and optimism in the reporting of outcomes. Finally, it should be noted that a large number (36/129, 28 .0%) of the included studies were from China. While the Chinese healthcare system is well-resourced in certain regions, many of the Chinese studies included were conducted in the city of Wuhan or in Hubei Province (n=9, 32.1%), where the gross domestic product per capita is less than half of that of Beijing and Shanghai. 144 Therefore, the findings of studies from China may be generalisable to the socioeconomic and health development status of other middle-income countries. This review contributes to the global understanding of paediatric COVID-19 disease and supports priority setting in research for current pandemic and future outbreaks. This body of literature would be improved by complete reporting of larger series with consecutive recruitment of patients, specific case definitions and complete long-term follow-up to determine global epidemiological trends, age-specific burden of disease and illness trajectory following COVID-19 infection. Improved characterisation of disease severity and increased reports from low-income countries are needed to better understand differences in clinical manifestations, resource utilisation and outcome by region, which can be integrated in future updated analyses. The concern for selection bias remains as it is possible that in LMICs, the population of hospitalised children was sicker and at higher baseline risk of death, independent of resources. Individual-patient-data meta-analysis would be of benefit to characterise risk factors for severe disease, clinical features in different age groups and account for observed differences in outcome. With respect to clinical management, none of the therapies instituted in the treatment of children with severe COVID-19 disease have been demonstrated to improve outcome in randomised trials; therefore, a recommendation regarding their use is challenging. Given that children appear less likely to develop severe respiratory disease, but are at risk of multiorgan dysfunction due to MIS-C, Global child health further studies are needed to characterise the clinical trajectory of this novel syndrome and determine the optimal treatment for it. Finally, there remains paucity of studies reporting long-term prognosis of COVID-19 in children. 145 Our review suggests that children predominantly contracted mild form of infection but could be at risk of more severe outcomes. It is crucial to take into consideration risk factors including contactexposure, underlying comorbidities, young age and male sex which may increase the risk of severe disease. While we have identified several elements that highlight the disease spectrum and higher risk of adverse outcomes in certain settings, such as LMICs, there is the need for much closer scrutiny of this illness globally with individual patient data analysis. Contributors ZB conceptualised the study and secured funding. ZSL and OI drafted the study protocol, conducted the literature search, study screening, selection and data extraction and drafted the manuscript. LJ and KT designed the data collection instruments, collected data, carried out data analyses and reviewed and revised the manuscript. FM drafted the initial manuscript and reviewed and revised the manuscript. All authors critically reviewed the manuscript for important intellectual content and approved the final manuscript as submitted. ZB is the guarantor. funding This review was funded in part by a grant from UNICEF (Headquarters) in partnership with the International Pediatric Association and with core support from the Centre for Global Child Health (Toronto) and the Center of Excellence in Women & Child Health, The Aga Khan University, Karachi, Pakistan Competing interests None declared. patient consent for publication Not required. provenance and peer review Not commissioned; internally peer reviewed. Data availability statement Data are available upon request supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http:// creativecommons. org/ licenses/ by-nc/ 4. 0/. Zulfiqar Bhutta http:// orcid. org/ 0000-0003-0637-599X referenCes Who coronavirus disease (COVID-19) Dashboard data last updated: 2021/1/21 Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China Coronavirus Disease 2019 in Children -United States COVID-19 in 7780 pediatric patients: a systematic review COVID-19 in children: an epidemiology study from China Clinical manifestations of children with COVID-19: a systematic review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents Multisystem inflammatory syndrome in U.S. children and adolescents Cardiac MRI in children with multisystem inflammatory syndrome associated with COVID-19 Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort Global Financing Facility for Women, Children and Adolescents (GFF) Quality assessment tool for observational cohort and cross-sectional studies. Bethesda: National Institutes of health, department of health and human services World bank country and lending groups (country classification Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China Clinical characteristics of children with coronavirus disease 2019 in Hubei, China Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features Novel coronavirus infection in hospitalized infants under 1 year of age in China The different clinical characteristics of corona virus disease cases between children and their families in China -the character of children with COVID-19 Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study Detection of Covid-19 in children in early Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing High-Resolution computed tomography manifestations of 5 pediatric patients with 2019 novel coronavirus Clinical and CT imaging features of the COVID-19 pneumonia: focus on pregnant women and children Three children who recovered from novel coronavirus 2019 pneumonia Detectable SARS-CoV-2 viral RNA in feces of three children during recovery period of COVID-19 pneumonia Insight into COVID-2019 for pediatricians Clinical features of pediatric patients with COVID-19: a report of two family cluster cases Screening and severity of coronavirus disease 2019 (COVID-19) in children in Differences in clinical and imaging presentation of pediatric patients with COVID-19 in comparison with adults COVID-19: four paediatric cases in Malaysia A case report of two children with corona virus disease 2019 complicated with diffuse intravascular coagulation A retrospective study of the clinical characteristics of COVID-19 infection in 26 children Clinical characteristics of a case series of children with coronavirus disease 2019 Clinical features of children with SARS-CoV-2 infection: an analysis of 13 cases from Changsha High resolution CT features of COVID-19 in children Novel coronavirus infection in children outside of Wuhan, China First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit Epidemiological and clinical characteristics of novel coronavirus infection in children: thoughts on the diagnostic criteria of suspected cases outside Hubei Province Hyperinflammatory shock in children during COVID-19 pandemic Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian pediatric intensive care units An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study COVID-19 infection in Iranian children: a case series of 9 patients Gastrointestinal features in children with COVID-19: an observation of varied presentation in eight children A wrinkle in time: how has management of pediatric cancers changed during COVID-19 in Pakistan? Novel coronavirus infection in newborn babies aged <28 days in China Neonatal early-onset infection with SARS-CoV-2 in 33 neonates born to mothers with COVID-19 in Wuhan, China Managing COVID-19-Positive maternalinfant dyads: an Italian experience Clinical characteristics of novel coronavirus pneumonia in children in Jinan Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center COVID-19 in pediatric patients: a case series Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series SARS-CoV-2 infection in children with febrile neutropenia Children in critical care due to severe acute respiratory syndrome coronavirus 2 infection: experience in a Spanish hospital Severe SARS-CoV-2 infection in children with suspected acute abdomen: a case series from a tertiary hospital in Spain Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department The first pediatric patients with coronavirus disease 2019 (COVID-19) in Japan: risk of co-infection with other respiratory viruses Pediatric coronavirus disease 2019 (COVID-19): an insight from West of Iran Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study Coronavirus disease 2019 in children Cared for at Texas children's Hospital: initial clinical characteristics and outcomes Neonates hospitalized with communityacquired SARS-CoV-2 in a Colorado neonatal intensive care unit COVID-19 in 17 Italian pediatric emergency departments Clinical features and treatment protocol in eleven Chinese children with mild COVID-19 Ethnicity and COVID-19 in children with comorbidities Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 SARS-CoV-2 infection in children COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study Children with Covid-19 in pediatric emergency departments in Italy Neurologic and radiographic findings associated with COVID-19 infection in children A preliminary report of COVID-19 in children in India Clinical features of critical coronavirus disease 2019 in children Clinical characteristics and outcome of SARS-CoV-2 infection in Italian pediatric oncology patients: a study from the infectious diseases Working group of the AIEOP COVID-19 in pediatric patients: a case series from the Bronx, NY Clinical manifestations and outcomes of critically ill children and adolescents with coronavirus disease COVID-19 in children in Brunei Darussalam: higher incidence but mild manifestations A multicenter national survey of children with SARS-CoV-2 infection admitted to Spanish pediatric intensive care units Early experience of COVID-19 in a US children's Hospital Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a multi-institutional study from New York City Multisystem inflammatory syndrome in children (MIS-C) associated with 2019 novel coronavirus (SARS-CoV-2) infection The epidemiological and clinical characteristics of 81 children with COVID-19 in a pandemic hospital in turkey: an observational cohort study Coronavirus disease 2019 in newborns and very young infants: a series of six patients in France Multi-Inflammatory syndrome in children related to SARS-CoV-2 in Spain COVID-19 multisystem inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection Laboratory-confirmed COVID-19 in children and youth in Canada Presentation of severe acute respiratory syndrome-coronavirus 2 infection as cholestatic jaundice in two healthy adolescents Epidemiological and clinical characteristics of COVID-19 in Indian children in the initial phase of the pandemic Multisystem inflammatory syndrome associated with COVID-19 in children in Pakistan Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study COVID-19 and multisystem inflammatory syndrome in Latin American children Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection Characteristics and management of children with COVID-19 in turkey Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study Multisystem inflammatory syndrome associated with coronavirus disease in children: a Multi-centered study in Belém First neonates with severe acute respiratory syndrome coronavirus 2 infection in Romania: three case reports Airborne transmission of SARS-CoV-2: theoretical considerations and available evidence SARS-CoV-2 testing and outcomes in the first 30 days after the first case of COVID-19 at an Australian children's hospital Clinical and laboratory characteristics of SARS-CoV2-infected paediatric patients in Jordan: serial RT-PCR testing until discharge Pediatric inflammatory multisystem syndrome (PIMS) did occur in Poland during months with low COVID-19 prevalence, preliminary results of a nationwide register The coronavirus disease 2019 (COVID-19) in children: a study in an Iranian children's referral hospital Multisystem inflammatory syndrome associated with SARS-CoV-2 infection in 45 children: a first report from Iran SARS-CoV-2 Infection in Infants Less than 90 Days Old Trisomy 21 and coronavirus disease 2019 in pediatric patients Multisystem inflammatory syndrome in children (MIS-C): report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic The direct and indirect impact of SARS-CoV-2 infections on neonates: a series of 26 cases in Bangladesh Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance Spectrum of neonatal COVID-19 in Iran: 19 infants with SARS-CoV-2 perinatal infections with varying test results, clinical findings and outcomes Convalescent plasma therapy in four critically ill pediatric patients with coronavirus disease 2019: a case series Multisystem Inflammatory Syndrome in Children, the Real Disease of COVID-19 in Pediatrics -A Multicenter Case Series From Al-Ahsa, Saudi Arabia 441. clinical characteristics of pediatric SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) in Kuwait Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study COVID-19 in the paediatric population of Kazakhstan COVID-19 in pediatrics: characteristics of hospitalized children in New Jersey Clinical spectrum of COVID-19 in a Mexican pediatric population Neonatal infection due to SARS-CoV-2: an epidemiological study in Spain Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection Epidemiological and Clinical Profile of Pediatric Inflammatory Multisystem Syndrome -Temporally Associated with SARS-CoV-2 (PIMS-TS) in Indian Children Kawasaki disease-like features in 10 pediatric COVID-19 cases: a retrospective study Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain Multisystem inflammatory syndrome in children with COVID-19 in Mumbai Clinical profile of SARS-CoV-2 infected neonates from a tertiary government hospital in Mumbai Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study COVID-19 in pediatric cancer patients in a resource-limited setting: national data from Peru COVID-19 in turkey: a tertiary center experience Clinical manifestations of children and adolescents with covid-19: report of the first 115 cases from sabará hospital infantil Multisystem inflammatory syndrome in children associated with novel coronavirus SARS-CoV-2: presentations to a pediatric emergency department in Michigan Clinical characteristics of 10 children with a pediatric inflammatory multisystem syndrome associated with COVID-19 in Iran Multisystem inflammatory syndrome in children in South Africa Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in Clinical experience with SARS CoV-2 related illness in children-hospital experience in Cape town, South Africa Clinical characteristics of acute respiratory syndrome with SARS-CoV-2 infection in children in South China COVID-19 and multisystem inflammatory syndrome in children and adolescents Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China An analysis of SARS-CoV-2 viral load by patient age Clinical characteristics and diagnostic challenges of pediatric COVID-19: a systematic review and meta-analysis Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19